Home Medizin Blutkrebsmedikament von GSK erreicht Hauptziel in später Phase der Studie; Analysten kündigen Comeback an

Blutkrebsmedikament von GSK erreicht Hauptziel in später Phase der Studie; Analysten kündigen Comeback an

von NFI Redaktion

(Reuters) – GSK announced on Thursday that a study has shown its experimental drug Blenrep has helped extend the survival of patients with a type of blood cancer without worsening symptoms, potentially signaling a comeback for the drug after several setbacks.

The pharmaceutical company’s shares rose by 2.6% to 17.17 pounds as of 1132 GMT – the highest level since August 2022.

GSK stated that an interim analysis of a late-stage study named „DREAMM-8“ showed that Blenrep in combination with Pomalidomide plus the steroid Dexamethasone increased progression-free survival compared to standard therapy.

The drug was tested in a study of 302 patients as a second-line therapy for patients with relapsed or refractory multiple myeloma.

GSK’s blood cancer drug Blenrep has faced several setbacks in recent years. In 2022, it was removed from the US market after failing a late-stage study intended to demonstrate its superiority to an existing treatment.

The failure had dealt a blow to GSK’s oncology portfolio, but analysts said the positive results on Thursday could signify a comeback for the drug.

„While we await further quantitative details, GSK plans to submit DREAMM-7/8 to regulatory authorities, which is likely to reintegrate Blenrep into models after largely removing it following previous failures,“ wrote Barclays analysts in a note.

Citi analysts forecast a risk-adjusted Blenrep revenue of 2.5 billion pounds (3.19 billion US dollars) in 2035.

(1 $ = 0.7839 pounds)

(Reporting by Yadarisa Shabong in Bengaluru; Editing by Shailesh Kuber)

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.